Singapore markets closed

Repare Therapeutics Inc. (RPTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.29-0.03 (-0.56%)
At close: 04:00PM EST
5.19 -0.10 (-1.89%)
After hours: 04:09PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 224.55M
Enterprise value -21.60M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)3.98
Price/book (mrq)0.96
Enterprise value/revenue -0.38
Enterprise value/EBITDA 0.21

Trading information

Stock price history

Beta (5Y monthly) 0.47
52-week change 3-67.30%
S&P500 52-week change 316.58%
52-week high 316.94
52-week low 33.08
50-day moving average 36.07
200-day moving average 39.18

Share statistics

Avg vol (3-month) 3344.01k
Avg vol (10-day) 3367.81k
Shares outstanding 542.13M
Implied shares outstanding 642.13M
Float 814.79M
% held by insiders 11.03%
% held by institutions 188.19%
Shares short (14 Nov 2023) 42.16M
Short ratio (14 Nov 2023) 44.41
Short % of float (14 Nov 2023) 48.64%
Short % of shares outstanding (14 Nov 2023) 45.12%
Shares short (prior month 12 Oct 2023) 41.57M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Sept 2023

Profitability

Profit margin -173.09%
Operating margin (ttm)-1,779.43%

Management effectiveness

Return on assets (ttm)-18.87%
Return on equity (ttm)-36.14%

Income statement

Revenue (ttm)56.28M
Revenue per share (ttm)1.34
Quarterly revenue growth (yoy)-98.10%
Gross profit (ttm)15.11M
EBITDA -103.09M
Net income avi to common (ttm)-97.42M
Diluted EPS (ttm)-2.31
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)250.07M
Total cash per share (mrq)5.94
Total debt (mrq)3.92M
Total debt/equity (mrq)1.68%
Current ratio (mrq)5.62
Book value per share (mrq)5.54

Cash flow statement

Operating cash flow (ttm)-128.64M
Levered free cash flow (ttm)-57.58M